Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.
2.

[Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].

Steffensen C, Mægbæk ML, Laurberg P, Andersen M, Kistorp C, Nørrelund H, Dal J, Jørgensen JO.

Ugeskr Laeger. 2014 Jan 6;176(1):58-60. Review. Danish.

PMID:
24629610
3.

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.

Antonini A, Poewe W.

Lancet Neurol. 2007 Sep;6(9):826-9. Review.

PMID:
17706566
4.

[Valvular heart disease associated with the treatment of Parkinson disease].

Rasmussen VG, Dupont E, Østergaard K, Egeblad H.

Ugeskr Laeger. 2006 Jun 26;168(26-32):2542-4. Review. Danish.

PMID:
16824407
5.

Cabergoline use for pituitary tumors and valvular disorders.

Auriemma RS, Pivonello R, Ferreri L, Priscitelli P, Colao A.

Endocrinol Metab Clin North Am. 2015 Mar;44(1):89-97. doi: 10.1016/j.ecl.2014.10.007. Epub 2014 Nov 4. Review.

PMID:
25732645
6.

[Cabergoline in hyperprolactinemia and valvular heart disease].

Vargas ML, Cervantes CE, Hernando CA, Da Costa CV.

Endocrinol Nutr. 2009 Oct;56(8):412-7. doi: 10.1016/S1575-0922(09)72711-1. Review. Spanish.

PMID:
19959151
7.

[Cardiac valvulopathy and dopamine agonist].

Grandas F.

Neurologia. 2007 Dec;22(10):870-81. Review. Spanish.

PMID:
17671852
8.

Drug-induced fibrotic valvular heart disease.

Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J.

Lancet. 2009 Aug 15;374(9689):577-85. doi: 10.1016/S0140-6736(09)60252-X. Review.

PMID:
19683643
9.

Use of the dopamine agonist cabergoline in the treatment of movement disorders.

Marco AD, Appiah-Kubi LS, Chaudhuri KR.

Expert Opin Pharmacother. 2002 Oct;3(10):1481-7. Review.

PMID:
12387694
10.
11.

Are there clinically significant differences between dopamine agonists.

Stocchi F, Vacca L, Onofrj M.

Adv Neurol. 2003;91:259-66. Review. No abstract available.

PMID:
12442684
12.

Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.

Valassi E, Klibanski A, Biller BM.

J Clin Endocrinol Metab. 2010 Mar;95(3):1025-33. doi: 10.1210/jc.2009-2095. Epub 2010 Feb 3. Review.

PMID:
20130078
13.

Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.

Kars M, Pereira AM, Bax JJ, Romijn JA.

Eur J Endocrinol. 2008 Oct;159(4):363-7. doi: 10.1530/EJE-08-0611. Epub 2008 Aug 14. Review.

14.

Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.

De Vecchis R, Esposito C, Ariano C.

Herz. 2013 Dec;38(8):868-80. doi: 10.1007/s00059-013-3816-0. Epub 2013 Jun 8. Review.

PMID:
23743769
15.

The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.

Caputo C, Prior D, Inder WJ.

Lancet Diabetes Endocrinol. 2015 Nov;3(11):906-13. doi: 10.1016/S2213-8587(14)70212-8. Epub 2014 Nov 14. Review. Erratum in: Lancet Diabetes Endocrinol. 2015 Nov;3(11):e10.

PMID:
25466526
16.

Drug-induced valvular heart disease.

Cosyns B, Droogmans S, Rosenhek R, Lancellotti P.

Heart. 2013 Jan;99(1):7-12. doi: 10.1136/heartjnl-2012-302239. Epub 2012 Aug 8. Review.

PMID:
22875739
17.

[Use of dopamine agonists in the treatment of Parkinson's disease].

Gekht AB.

Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(9):54-8. Review. Russian. No abstract available.

PMID:
12378886
18.

[Pharmacological effects of cabergoline against parkinsonism].

Ichikawa K, Kojima M.

Nihon Yakurigaku Zasshi. 2001 Jun;117(6):395-400. Review. Japanese.

PMID:
11436517
19.

Cabergoline : a review of its use in the treatment of Parkinson's disease.

Curran MP, Perry CM.

Drugs. 2004;64(18):2125-41. Review.

PMID:
15341508
20.

[Are there innovations in the treatment of Parkinson's disease?].

Ludin HP.

Praxis (Bern 1994). 2004 Nov 3;93(45):1865-8. Review. German.

PMID:
15571301

Supplemental Content

Support Center